New hope for stomach pain? itopride study launches

NCT ID NCT07165301

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 200 people with functional dyspepsia, a common stomach disorder causing fullness and pain after meals. Participants will take itopride as part of their normal care. Researchers will track symptom changes over 16 weeks to see if the drug helps in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

itopride

What this could lead to

If it works, this could confirm that itopride helps ease symptoms of functional dyspepsia in Western patients, offering a new treatment option.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. Itopride's effectiveness in Western populations is still uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNCTIONAL DYSPEPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dyspepsia functional gastric disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UZ Leuven

    Leuven, 3000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••